Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain zaps get smarter: AI-Powered TMS aims to ease chronic pain

NCT ID NCT07103135

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a faster form of brain stimulation (accelerated TMS) for people with long-term chronic pain that hasn't improved with medication. Researchers will use a smart algorithm to choose the best spot to stimulate each person's brain, based on their individual pain patterns. The goal is to see if this personalized approach is safe and can reduce pain intensity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18 years or older * Ability to provide written informed consent * Ability to read and to communicate verbally and in writing in English * Chronic pain persisting for at least 12 months * Pain refractory to oral pain medication (defined as failing at least two different medication classes) * Average pain intensity of ≥5 on the Numerical Rating Scale (NRS) over the past two weeks * Stable pain medication regimen for at least 4 weeks prior to enrollment * Willing and able to attend all study visits and comply with study procedures Exclusion Criteria: * Current substance use disorder (except for nicotine or cannabis) as determined by DSM-5 criteria * Active suicidal ideation with intent or plan as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) * Lifetime history of bipolar disorder, schizophrenia, or other psychotic disorder as determined by medical history * Self-reported unstable medical conditions that would pose increased risks for TMS or MRI * Pregnancy (as determined by urine pregnancy test) or planned pregnancy during the study period * Contraindications to TMS, including: * History of seizure or epilepsy * Metallic implants in the head (excluding dental fillings) * Cardiac pacemaker or other implanted medical devices * History of significant head trauma * History of intracranial surgery * Medication that significantly lowers seizure threshold that cannot be safely held * Contraindications to MRI, including: * Claustrophobia * Metallic implants or devices * Inability to lie flat for the duration of the scan * Current use of high-dose opioids (\>90 morphine milligram equivalents daily) * Participation in another clinical trial of an investigational medication or device within 30 days prior to enrollment * Any condition that, in the investigator\'s opinion, would make it unsafe or difficult for the participant to complete the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.